SCHEMBL17425979

SCHEMBL17425979

OCc1cnn2ccc(CN3NNc4ncc(-c5cnn(CCOC6CCCCO6)c5)nc43)cc12

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.43
KDM4C Q9H3R0 1/20 0.30
P2RX3 P56373 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17425975 0.89 MET (0.44) METKDM4CP2RX3
SCHEMBL16882542 0.84 MET (0.46) MET
SCHEMBL2177639 0.83 MET (0.54) MET
SCHEMBL29773372 0.76 MET (0.50) MET
SCHEMBL12483227 0.76 MET (0.50) MET
SCHEMBL2178001 0.75 MET (0.48) MET
SCHEMBL12690022 0.74 MET (0.52) MET
SCHEMBL22475682 0.73 MET (0.42) MET
SCHEMBL2177521 0.72 MET (0.50) MET
SCHEMBL16882492 0.71 MET (0.53) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2966075-A1 CERTAIN TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CANCER. Hutchison Medipharma Limited (CN) 2016-01-13 EP disclosed